Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · AbCellera Biologics Inc. (ABCL)

AbCellera to report Phase 2 ABCL635 menopause hot flash data on August 10, 2026

Neutral Impact 3 of 5 product/contract Written later

AbCellera said it will release top-line results from its Phase 2 trial of ABCL635, an antibody drug for moderate-to-severe vasomotor symptoms (hot flashes) due to menopause, before the market opens on Monday, August 10, 2026. The company will also hold an investor conference call and webcast that morning at 4:30 a.m. Pacific Time. The filing contains no trial results, so the announcement itself does not yet show whether the drug worked, but the data will be a key test for the program's future.

Key points

  • Top-line Phase 2 data for ABCL635 to be released before market open on Monday, August 10, 2026
  • Investor conference call and live webcast at 4:30 a.m. PT / 7:30 a.m. ET the same day
  • Trial (NCT07118891) is randomized, double-blind and placebo-controlled with approximately 80 postmenopausal women

The filing

CompanyAbCellera Biologics Inc. (ABCL)
Form8-K, current report
Filed with the SECAug 7, 2026, 4:43 PM ET
Accession number0001703057-26-000049

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 07, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.